Publication Cover
Spectroscopy Letters
An International Journal for Rapid Communication
Volume 28, 1995 - Issue 3
16
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

NMR Studies of Drugs. Applications of Achiral and Chiral Lanthanide Shift Reagents to Medetomidine. Observations of “Anomalous Shifts.”

, &
Pages 379-394 | Received 11 Oct 1994, Accepted 24 Nov 1994, Published online: 23 Sep 2006
 

Abstract

The 60 MHz H NMR spectra of the potent, selective and specific α2-adrenoceptor agonist, medetomidine, have been studied in CDCl3 at 28±1° for the recemic free base, 1, with the added achiral lanthanide shift reagent (LSR), tris(6,6,7,7,8,8,8-heptafluoro-2,2-dimethyl-3,5-octanedionato) europium(III), 2, for spectral simplification, and with the chiral LSRs, tris[3-(heptafluoropropylhydroxymethylene)-(+)-camphorato]europium(III), 3, and tris[3-(trifluoromethylhydroxymethylene)-(+)-camphorato] europium (III), 4, for potential enantiomeric shift differences. Substantial lanthanide-induced shifts (LIS) were observed with each added LSR, consistent with LSR binding at the basic imidazole nitrogen. The three LSRs gave distinctly different LIS results for the NH signal, with substantial “anomalous” (upfield) shifts observed with 2 and smaller anomalous shifts produced with 3, at low [LSR]:[1] ratios; normal downfield shifts resulted at higher LSR levels of 2 or 3. With LSR 4, only consistent “normal” downfield shifts were seen for the NH signal.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.